Clinical Trials
6 trialsNCT03013491 2025-06-17
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
Phase 1/2 Terminated
NCT01683188 2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4 Terminated
NCT01616199 2018-05-16
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Seagen Inc.
Phase 1/2 Terminated
NCT01586195 2017-05-25
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Genentech, Inc.
Phase 2 Terminated
NCT01519323 2016-10-10
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Hoffmann-La Roche
Phase 1 Terminated
NCT01400451 2015-01-01
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Bristol-Myers Squibb
Phase 1 Terminated